SCHEMBL15918396

SCHEMBL15918396

Clc1nccc(NCc2ccc(N3CCOCC3)cc2)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK4 O00444 2/20 0.61
ACHE P22303 5/20 0.60
KDM4E B2RXH2 2/20 0.53
MAPT P10636 2/20 0.53
ALOX12 P18054 2/20 0.53
HTT P42858 1/20 0.53
CXCR4 P61073 1/20 0.52
CYP11B2 P19099 1/20 0.51
GAA P10253 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
RAB9A P51151 2/20 0.50
NPC1 O15118 1/20 0.50
ALDH1A1 P00352 1/20 0.50
ALOX15 P16050 1/20 0.50
MAPK1 P28482 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
JAK2 O60674 1/20 0.47
JAK1 P23458 1/20 0.47
KIT P10721 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6982507 0.80 PLK4 (0.67) PLK4KDM4EMAPTMAPK1SMN1; SMN2
SCHEMBL14554975 0.79 CLK4 (0.53) PLK4ACHEKDM4EMAPTALOX12
SCHEMBL30854964 0.77 CXCR4 (0.64) PLK4ACHEKDM4EMAPTALOX12
SCHEMBL8241275 0.77 KDM4E (0.58) ACHEKDM4EMAPTGAARAB9A
SCHEMBL23887632 0.75 PLK4 (0.74) PLK4JAK2AURKAAURKBJAK3
SCHEMBL4648432 0.75 ALDH1A1 (0.54) ACHEKDM4EALDH1A1MAPK1
SCHEMBL14554956 0.75 CLK4 (0.53) PLK4ACHEKDM4EMAPTALOX12
SCHEMBL15260237 0.75 CYP1A2 (0.67) KDM4EMAPTCXCR4L3MBTL1ALDH1A1
SCHEMBL30854968 0.75 KDM4E (0.57) PLK4ACHEKDM4EMAPTALOX12
SCHEMBL1666752 0.74 CYP1A2 (0.64) ACHEKDM4EMAPTALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2729459-B1 SUBSTITUTED AZAHETEROCYCLES FOR THE TREATMENT OF CANCER MERCK PATENT GMBH (DE) 2018-08-22 EP disclosed
US-9199962-B2 Substituted azaheterocycles for the treatment of cancer MERCK PATENT GMBH (DE) 2015-12-01 US disclosed
US-9199962-B2 Substituted azaheterocycles for the treatment of cancer MERCK PATENT GMBH (DE) 2015-12-01 US disclosed
US-9199962-B2 Substituted azaheterocycles for the treatment of cancer MERCK PATENT GMBH (DE) 2015-12-01 US disclosed
US-20140221366-A1 Substituted Azaheterocycles for the Treatment of Cancer MERCK PATENT GMBH (DE) 2014-08-07 US disclosed
US-20140221366-A1 Substituted Azaheterocycles for the Treatment of Cancer MERCK PATENT GMBH (DE) 2014-08-07 US disclosed
US-20140221366-A1 Substituted Azaheterocycles for the Treatment of Cancer MERCK PATENT GMBH (DE) 2014-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221366-A1 Substituted Azaheterocycles for the Treatment of Cancer CCNH, CCNA1, MYC PLK4 3040/4885ACHE 4885/4885KDM4E 876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.